{"organizations": [], "uuid": "40a1aae4696e6cf45cb51abce9a5c23954e16a45", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "https://fm.cnbc.com/applications/cnbc.com/resources/img/editorial/2015/03/20/102523530-biogen.600x400.jpg", "site_section": "http://www.cnbc.com/id/15839263/device/rss/rss.html", "section_title": "Top Video", "url": "https://www.cnbc.com/video/2018/01/08/biogen-ceo-we-need-to-be-the-tesla-of-drug-pricing-model.html", "country": "US", "domain_rank": 767, "title": "Biogen CEO: We need to be the 'Tesla' of drug pricing model", "performance_score": 0, "site": "cnbc.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T15:35:00.000+02:00", "replies_count": 0, "uuid": "40a1aae4696e6cf45cb51abce9a5c23954e16a45"}, "author": "", "url": "https://www.cnbc.com/video/2018/01/08/biogen-ceo-we-need-to-be-the-tesla-of-drug-pricing-model.html", "ord_in_thread": 0, "title": "Biogen CEO: We need to be the 'Tesla' of drug pricing model", "locations": [], "entities": {"persons": [{"name": "tesla", "sentiment": "negative"}, {"name": "michel vounatsos", "sentiment": "none"}, {"name": "vounatsos", "sentiment": "none"}, {"name": "meg tirrell", "sentiment": "none"}, {"name": "trump", "sentiment": "none"}], "locations": [], "organizations": [{"name": "cnbc", "sentiment": "negative"}, {"name": "biogen", "sentiment": "negative"}, {"name": "j.p. morgan health care conference", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Biogen CEO: We need to be the 'Tesla' of drug pricing model 2 Hours Ago In an exclusive CNBC interview Michel Vounatsos, Biogen CEO talks to CNBC's Meg Tirrell at the J.P. Morgan Health Care Conference about investing in health care under President Trump and the impact of tax reform on mergers and acquisition. Also Vounatsos weighs in on Biogen's drug pipeline and drug pricing.", "external_links": [], "published": "2018-01-08T15:35:00.000+02:00", "crawled": "2018-01-08T18:25:49.012+02:00", "highlightTitle": ""}